Meeder Asset Management Inc Seagen Inc. Transaction History

Meeder Asset Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $135 - $180	1 Added 2.86%	36 $5,000
Q2 2022 Aug 08, 2022	SELL	$108.81 - $179.33 $761 - $1,255	-7 Reduced 16.67%	35 $6,000
Q1 2022 May 10, 2022	BUY	$119.61 - $157.85 $1,076 - $1,420	9 Added 27.27%	42 $6,000
Q4 2021 Feb 11, 2022	SELL	$142.57 - $190.86 $667,370 - $893,415	-4,681 Reduced 99.3%	33 $5,000
Q3 2021 Nov 08, 2021	SELL	$142.45 - $169.82 $4,985 - $5,943	-35 Reduced 0.74%	4,714 $801,000

Q2 2021 Aug 09, 2021	SELL	$135.08 - $161.1 $120,491 - $143,701	-892 Reduced 15.81%	4,749 $750,000
Q1 2021 Apr 28, 2021	BUY	$137.51 - $190.8 $765,243 - $1.06 Million	5,565 Added 7322.37%	5,641 $783,000
Q4 2020 Feb 09, 2021	BUY	$164.63 - $211.93 $12,511 - $16,106	76 New	76 $13,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.